The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.

PubWeight™: 11.08‹?› | Rank: Top 0.1%

🔗 View Article (PMID 7753136)

Published in N Engl J Med on June 15, 1995


G A Colditz1, S E Hankinson, D J Hunter, W C Willett, J E Manson, M J Stampfer, C Hennekens, B Rosner, F E Speizer

Author Affiliations

1: Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Boston.

Associated clinical trials:

Effect of DHEA on Skin Aging in Postmenopausal Women | NCT00248989

Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model | NCT04051320

Articles citing this

(truncated to the top 100)

Breast cancer and hormonal supplements in postmenopausal women. BMJ (1995) 4.16

The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause (2012) 4.04

Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA (2011) 3.85

Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol (2012) 3.56

Evidence-based common sense? Can Fam Physician (2008) 2.67

Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. J Natl Cancer Inst (2013) 2.45

Utilisation of hormone replacement therapy by women doctors. BMJ (1995) 2.35

Current and potential future drug treatments for osteoporosis. Ann Rheum Dis (1996) 2.21

Does sexual dimorphism in human faces signal health? Proc Biol Sci (2003) 2.02

Identifying patient preferences for communicating risk estimates: a descriptive pilot study. BMC Med Inform Decis Mak (2001) 1.88

Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of Gastroenterology. Gut (2000) 1.81

Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis. Menopause (2006) 1.71

Prevention. How much harm? How much benefit? 1. Influence of reporting methods on perception of benefits. CMAJ (1996) 1.69

Hormone replacement therapy: assessment of present use, costs, and trends. Br J Gen Pract (1998) 1.67

Potential mechanisms of estrogen quinone carcinogenesis. Chem Res Toxicol (2007) 1.56

Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort. Cancer Epidemiol Biomarkers Prev (2008) 1.55

Breast cancer risk factors in relation to breast density (United States). Cancer Causes Control (2006) 1.54

Age at menopause: imputing age at menopause for women with a hysterectomy with application to risk of postmenopausal breast cancer. Ann Epidemiol (2011) 1.51

Recent trends in breast cancer mortality among white and black US women. Am J Public Health (1997) 1.48

Menopausal hormone therapy and breast cancer: what is the true size of the increased risk? Br J Cancer (2016) 1.47

Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res (2009) 1.47

Postmenopausal Female Hormone Use and Estrogen Receptor-Positive and -Negative Breast Cancer in African American Women. J Natl Cancer Inst (2015) 1.44

Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 3. Effects of ovarian hormone therapy on skeletal and extraskeletal tissues in women. CMAJ (1996) 1.43

Female hepatology: favorable role of estrogen in chronic liver disease with hepatitis B virus infection. World J Gastroenterol (2007) 1.43

Changing concepts: Menopausal hormone therapy and breast cancer. J Natl Cancer Inst (2012) 1.39

What is newsworthy? Bad news from research really is headline news. BMJ (2002) 1.38

Disparities in mammographic screening for Asian women in California: a cross-sectional analysis to identify meaningful groups for targeted intervention. BMC Cancer (2007) 1.32

Prediagnostic use of hormone therapy and mortality after breast cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.25

A prospective study of postmenopausal hormone use and ovarian cancer risk. Br J Cancer (2006) 1.23

Mechanisms of cyclin-dependent kinase inactivation by progestins. Mol Cell Biol (1998) 1.20

Long-term cancer risk in women given diethylstilbestrol (DES) during pregnancy. Br J Cancer (2001) 1.19

Body mass index and post-menopausal breast cancer: an age-specific analysis. Br J Cancer (1997) 1.19

Ultrafiltration tandem mass spectrometry of estrogens for characterization of structure and affinity for human estrogen receptors. J Am Soc Mass Spectrom (2005) 1.15

Ethnic differences in hormone replacement prescribing patterns. J Gen Intern Med (1999) 1.10

Antioxidative and chemopreventive properties of Vernonia amygdalina and Garcinia biflavonoid. Int J Environ Res Public Health (2011) 1.10

Menstrual cycle characteristics and incidence of premenopausal breast cancer. Cancer Epidemiol Biomarkers Prev (2005) 1.08

Redox cycling of catechol estrogens generating apurinic/apyrimidinic sites and 8-oxo-deoxyguanosine via reactive oxygen species differentiates equine and human estrogens. Chem Res Toxicol (2010) 1.07

Estrogen action: a historic perspective on the implications of considering alternative approaches. Physiol Behav (2009) 1.07

Soy isoflavone supplementation and bone mineral density in menopausal women: a 2-y multicenter clinical trial. Am J Clin Nutr (2009) 1.06

Criteria for the evaluation of large cohort studies: an application to the nurses' health study. J Natl Cancer Inst (2008) 1.06

Hormone replacement therapy and tumour grade in breast cancer: prospective study in screening unit. BMJ (1996) 1.03

Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. Am J Med (2011) 1.02

How does hormone replacement therapy affect the longevity of women with different risk profiles? Can Fam Physician (1997) 1.02

Risk factors for ductal and lobular breast cancer: results from the nurses' health study. Breast Cancer Res (2010) 1.02

Estrogen Receptor {alpha} Enhances the Rate of Oxidative DNA Damage by Targeting an Equine Estrogen Catechol Metabolite to the Nucleus. J Biol Chem (2009) 0.99

Trends of postmenopausal estrogen plus progestin prevalence in the United States between 1970 and 2010. Obstet Gynecol (2014) 0.99

Mammographic screening and risk factors for breast cancer. Am J Epidemiol (2009) 0.99

Causes of Alzheimer's disease. CMAJ (2000) 0.98

Menopausal hormones and breast cancer in a biracial population. Am J Public Health (2000) 0.98

What is osteoporosis? Postgrad Med J (2003) 0.95

Mortality following development of breast cancer while using oestrogen or oestrogen plus progestin: a computer record-linkage study. Br J Cancer (2005) 0.95

Age-related variation in the relationship between menopausal hormone therapy and the risk of dying from breast cancer. Breast Cancer Res Treat (2010) 0.95

A phytoestrogen diarylheptanoid mediates estrogen receptor/Akt/glycogen synthase kinase 3β protein-dependent activation of the Wnt/β-catenin signaling pathway. J Biol Chem (2012) 0.94

Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women. J Bone Miner Metab (2006) 0.93

Hormone-associated cancer: mechanistic similarities between human breast cancer and estrogen-induced kidney carcinogenesis in hamsters. Environ Health Perspect (1997) 0.92

Effects of two estradiol regimens on anxiety and depressive behaviors and trophic effects in peripheral tissues in a rodent model. Gend Med (2009) 0.91

Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin. Breast Cancer Res (2007) 0.91

Results of observational studies: analysis of findings from the Nurses' Health Study. PLoS One (2014) 0.91

Validation of Rosner-Colditz breast cancer incidence model using an independent data set, the California Teachers Study. Breast Cancer Res Treat (2013) 0.90

Translesion synthesis past equine estrogen-derived 2'-deoxyadenosine DNA adducts by human DNA polymerases eta and kappa. Biochemistry (2006) 0.90

Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease. Mov Disord (2009) 0.90

Large-scale hormone replacement therapy and life expectancy: results from an international comparison among European and North American populations. Am J Public Health (2000) 0.89

Mechanism of translesion synthesis past an equine estrogen-DNA adduct by Y-family DNA polymerases. J Mol Biol (2007) 0.89

Postmenopausal hormone therapy as a risk factor for gastroesophageal reflux symptoms among female twins. Gastroenterology (2008) 0.88

Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations. Fam Cancer (2004) 0.88

Bilateral acute anterior uveitis after alendronate. Br J Ophthalmol (2002) 0.88

4-hydroxyequilenin-adenine lesions in DNA duplexes: stereochemistry, damage site, and structure. Biochemistry (2007) 0.88

Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro. Br J Pharmacol (2007) 0.87

Progesterone receptors--animal models and cell signalling in breast cancer. Implications for breast cancer of inclusion of progestins in hormone replacement therapies. Breast Cancer Res (2002) 0.87

Roles of hormone replacement therapy and iron in proliferation of breast epithelial cells with different estrogen and progesterone receptor status. Breast (2007) 0.87

Hormone-replacement therapy--breast versus heart versus bone. N Engl J Med (1995) 0.87

Hormone therapy and young-onset breast cancer. Am J Epidemiol (2015) 0.87

Initiation of hormone replacement therapy after diagnosis of osteoporosis by bone densitometry. Osteoporos Int (1997) 0.87

Use of hormone replacement therapy. Evidence on risk of breast cancer associated with hormone replacement therapy is still inconclusive. BMJ (1996) 0.86

A Theory-Based Model for Predicting Adherence to Guidelines for Screening Mammography among Women Age 40 and Older. Int J Canc Prev (2005) 0.85

Screening mammography intervals among postmenopausal hormone therapy users and nonusers. Cancer Causes Control (2009) 0.85

Selective estrogen receptor modulator delivery of quinone warheads to DNA triggering apoptosis in breast cancer cells. ACS Chem Biol (2009) 0.85

Conformational properties of equilenin-DNA adducts: stereoisomer and base effects. Chem Res Toxicol (2008) 0.84

Divergent mechanisms for trophic actions of estrogens in the brain and peripheral tissues. Brain Res (2010) 0.84

Hormone replacement therapy and the breast. BMJ (2001) 0.84

Changes of the prescription of hormone therapy in menopausal women: an observational study in Taiwan. BMC Public Health (2007) 0.84

A population-based cohort study of HRT use and breast cancer in southern Sweden. Br J Cancer (2001) 0.84

Polymorphisms of caffeine metabolism and estrogen receptor genes and risk of Parkinson's disease in men and women. Parkinsonism Relat Disord (2010) 0.83

Increased risk for invasive breast cancer associated with hormonal therapy: a nation-wide random sample of 65,723 women followed from 1997 to 2008. PLoS One (2011) 0.83

Incidence and causes for failure of treatment of women with proven osteoporosis. Osteoporos Int (2005) 0.83

Effect of osteoporosis medications on fracture healing. Osteoporos Int (2015) 0.83

The contribution of postmenopausal hormone use cessation to the declining incidence of breast cancer. Cancer Causes Control (2010) 0.83

Digoxin use and risk of invasive breast cancer: evidence from the Nurses' Health Study and meta-analysis. Breast Cancer Res Treat (2014) 0.82

Estradiol enhances sociosexual behavior and can have proliferative effects in ovariectomized rats. Age (Dordr) (2008) 0.81

Prescribing menopausal hormone therapy: an evidence-based approach. Int J Womens Health (2014) 0.81

Mining cancer-specific disease comorbidities from a large observational health database. Cancer Inform (2014) 0.81

Emodin and Aloe-Emodin Suppress Breast Cancer Cell Proliferation through ER α Inhibition. Evid Based Complement Alternat Med (2013) 0.80

Development of a liquid chromatography electrospray ionization tandem mass spectrometry method for analysis of stable 4-hydroxyequilenin-DNA adducts in human breast cancer cells. Chem Res Toxicol (2009) 0.80

+331G/A variant in the progesterone receptor gene, postmenopausal hormone use and risk of breast cancer. Int J Cancer (2009) 0.80

Raloxifene and/or estradiol decrease anxiety-like and depressive-like behavior, whereas only estradiol increases carcinogen-induced tumorigenesis and uterine proliferation among ovariectomized rats. Behav Pharmacol (2010) 0.80

Levetiracetam for the treatment of hot flashes: a phase II study. Support Care Cancer (2007) 0.79

Hormone replacement therapy again. Risk-benefit relation differs between populations and individuals. BMJ (1998) 0.79

Screening women at increased risk with MRI. Cancer Imaging (2005) 0.79

Why do women doctors in the UK take hormone replacement therapy? J Epidemiol Community Health (1997) 0.79

Evidence for gender differences in cognition, emotion and quality of life in Parkinson's disease? Aging Dis (2013) 0.79

Articles by these authors

An association between air pollution and mortality in six U.S. cities. N Engl J Med (1993) 38.84

Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol (1985) 26.13

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med (1997) 18.85

Reproducibility and validity of an expanded self-administered semiquantitative food frequency questionnaire among male health professionals. Am J Epidemiol (1992) 17.17

Total energy intake: implications for epidemiologic analyses. Am J Epidemiol (1986) 16.34

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA (2001) 15.85

Particulate air pollution as a predictor of mortality in a prospective study of U.S. adults. Am J Respir Crit Care Med (1995) 15.80

Observations on recent increase in mortality from asthma. Br Med J (1968) 14.82

Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med (2001) 14.48

Body weight and mortality among women. N Engl J Med (1995) 11.04

OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage (2008) 10.99

Food-based validation of a dietary questionnaire: the effects of week-to-week variation in food consumption. Int J Epidemiol (1989) 10.98

Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. Am J Epidemiol (1986) 10.84

Validity of self-reported waist and hip circumferences in men and women. Epidemiology (1990) 10.57

Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet (1998) 10.11

Reproducibility and validity of a self-administered physical activity questionnaire. Int J Epidemiol (1994) 9.90

Reproducibility and validity of food intake measurements from a semiquantitative food frequency questionnaire. J Am Diet Assoc (1993) 9.90

Aspirin and the risk of colorectal cancer in women. N Engl J Med (1995) 9.59

Dietary fat and coronary heart disease: a comparison of approaches for adjusting for total energy intake and modeling repeated dietary measurements. Am J Epidemiol (1999) 9.34

Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J (1985) 9.28

Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med (2000) 9.05

Relation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among women. N Engl J Med (1990) 8.98

No hiding place: on the discomforts of researching the contemporary policy process. J Soc Policy (1990) 8.97

Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med (1991) 8.66

Prospective study of alcohol consumption and risk of coronary disease in men. Lancet (1991) 8.64

Annual deaths attributable to obesity in the United States. JAMA (1999) 8.62

A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA (1995) 8.60

Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med (1996) 8.57

Test of the National Death Index. Am J Epidemiol (1984) 8.46

Dietary fat intake and the risk of coronary heart disease in women. N Engl J Med (1997) 8.43

Misinterpretation and misuse of the kappa statistic. Am J Epidemiol (1987) 8.29

Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation (2000) 8.17

Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet (2013) 8.16

Evidence based policymaking. BMJ (1995) 8.08

The Nurses' Health Study: 20-year contribution to the understanding of health among women. J Womens Health (1997) 8.00

Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. Lancet (1991) 7.87

A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol (1993) 7.73

Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med (1995) 7.62

OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage (2010) 7.52

Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care (1994) 7.11

Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA (1998) 7.09

Reproducibility and validity of dietary patterns assessed with a food-frequency questionnaire. Am J Clin Nutr (1999) 7.02

Plasma organochlorine levels and the risk of breast cancer. N Engl J Med (1997) 7.02

Dietary fiber, glycemic load, and risk of non-insulin-dependent diabetes mellitus in women. JAMA (1997) 6.92